Chondroitinase treatment following spinal contusion injury increases migration of oligodendrocyte progenitor cells

Siebert, Justin R.; Stelzner, Dennis J.; Osterhout, Donna J.

doi:10.1016/j.expneurol.2011.05.002

Cited by 85 publications

(79 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kwon et al [2001]) were tested in a rodent contusion model of the spinal cord. Briefly, a moderate contusion injury was generated using an impactor rod drop with an NYU impactor [Siebert et al, 2011] in the T9-T11 region of the rat spinal cord. Immediately after the injury, 3 μl of a 20-mg/ml suspension of nanoparticles were injected into the rostral and caudal edges of the lesion along the midline using a microinjection apparatus.…”

Section: Use Of Chabc-releasing Nanoparticles Within a Rodent Model Omentioning

confidence: 99%

“…The animals were sacrificed at various times postinjury to evaluate the extent of chABC release from nanospheres and proteoglycan digestion in vivo. The in vivo release of chABC from nanoparticles was detected by immunohistochemistry for the CSPGs in their native form or cleaved forms of CSPGs using the antibody CS56 (identifies undigested CSPG) or 2B6 (identifies chABC-digested CSPGs) [Siebert et al, 2011]. The lesion site can be outlined in spinal cord sections by immunostaining for GFAP (glial fibrillary acidic protein), which identifies the reactive astrocytes surrounding the lesion site.…”

Section: Use Of Chabc-releasing Nanoparticles Within a Rodent Model Omentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle Technologies in the Spinal Cord

Zuidema

Gilbert²,

Osterhout

2016

Cells Tissues Organs

Self Cite

View full text Add to dashboard Cite

Nanoparticles are increasingly being studied within experimental models of spinal cord injury (SCI). They are used to image cells and tissue, move cells to specific regions of the spinal cord, and deliver therapeutic agents locally. The focus of this article is to provide a brief overview of the different types of nanoparticles being studied for spinal cord applications and present data showing the capability of nanoparticles to deliver the chondroitinase ABC (chABC) enzyme locally following acute SCI in rats. Nanoparticles releasing chABC helped promote axonal regeneration following injury, and the nanoparticles also protected the enzyme from rapid degradation. In summary, nanoparticles are viable materials for diagnostic or therapeutic applications within experimental models of SCI and have potential for future clinical use.

show abstract

Section: Use Of Chabc-releasing Nanoparticles Within a Rodent Model Omentioning

confidence: 99%

Section: Use Of Chabc-releasing Nanoparticles Within a Rodent Model Omentioning

confidence: 99%

Nanoparticle Technologies in the Spinal Cord

Zuidema

Gilbert²,

Osterhout

2016

Cells Tissues Organs

Self Cite

View full text Add to dashboard Cite

show abstract

“…Because it is known that CSPGs also inhibit axonal regeneration, and perturbation of CSPGs promotes axonal sprouting [128,129], it could be argued that increased remyelination after xyloside treatment is a consequence of increased axonal targets for new sheath development and not per se true remyelination. However, at least in spinal cord injury models, the kinetics of axonal sprouting and OPC invasion are discordant, suggesting that the 2 events are independent and CSPG disruption could indeed directly promote remyelination [130].…”

Section: Extracellular Matrix Moleculesmentioning

confidence: 99%

“…Alternatively, the receptors that bind CSPGs, including protein tyrosine phosphatase-σ, leukocyte common antigen-related phosphatase, or Nogo-66 receptor 1 and 3, could potentially be targets for the development of antagonistic inhibitors [133][134][135]. It is important to note that the majority of work investigating CSPG-mediated inhibition has been focused on growth of neurites after traumatic injuries, and inhibition of OPCs by CSPGs has only recently been put in the spotlight [126,127,130]. Whether similar or different mechanisms mediate CSPG inhibition of neurons versus OPCs awaits further study.…”

Section: Extracellular Matrix Moleculesmentioning

confidence: 99%

Remyelination Therapy for Multiple Sclerosis

Keough

Yong

2013

Neurotherapeutics

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system characterized by infiltration of immune cells and progressive damage to myelin and axons. All therapeutics used to treat MS have been developed to target an overactive immune response, with aims to reduce disease activity. Chronic demyelinated axons are further prone to irreversible damage and death, and it is imperative that new therapies address this critical issue. Remyelination, the generation of new myelin in the adult nervous system, is an endogenous repair mechanism that restores function of denuded axons and delays their deterioration. Although remyelination can be extensive in some patients, the majority of cases limit repair only to the acute phase of disease. A significant current drive in new MS therapeutics is to identify targets that can promote remyelination by boosting endogenous oligodendrocyte precursor cells to form new myelin. Also, a number of inhibitory pathways have been identified in chronic MS lesions that prevent oligodendrocyte precursor cells from being properly recruited to demyelinated lesions or interfere with their differentiation to myelin-forming oligodendrocytes. In this review, we introduce the phenomenon of remyelination from the view of experimental models and studies in MS patients, describe a potential role in remyelination for currently available MS mediations, and discuss many avenues that are being actively studied to promote remyelination. The next frontier in MS therapeutics will supplement immunomodulation with agents that directly foster myelin repair, with aims to delay disease progression and recover lost neurological functions.

show abstract

“…Trabalhos mais atuais apostam na resolução da cicatriz da glia associadas às terapias com células-tronco para o tratamento da lesão medular crônica (IKEGAMI et al, 2005;SIEBERT et al, 2011 …”

Section: Discussionunclassified

O uso de condroitinase ABC combinada com células-tronco do epitélio olfatório de coelhos em modelo de lesão medular por hemissecção dorsal em coelhos

Bocabello¹

View full text Add to dashboard Cite

Chondroitinase treatment following spinal contusion injury increases migration of oligodendrocyte progenitor cells

Cited by 85 publications

References 32 publications

Nanoparticle Technologies in the Spinal Cord

Nanoparticle Technologies in the Spinal Cord

Remyelination Therapy for Multiple Sclerosis

O uso de condroitinase ABC combinada com células-tronco do epitélio olfatório de coelhos em modelo de lesão medular por hemissecção dorsal em coelhos

Contact Info

Product

Resources

About